Tesamorelin
Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH), carrying an N-terminal trans-3-hexenoyl modification that increases its resistance to enzymatic degradation relative to the native hormone. It is studied for its interaction with pituitary GHRH receptors and downstream endpoints in the growth hormone / IGF-1 axis. For laboratory research use only.
Available Options
Research Context
Tesamorelin is a synthetic analog of the full-length 44-amino-acid human growth hormone-releasing hormone, modified by attachment of a trans-3-hexenoyl group at the N-terminal tyrosine residue. This modification protects the peptide from rapid cleavage by dipeptidyl peptidase IV, extending its functional half-life relative to native GHRH while retaining agonist activity at the pituitary GHRH receptor. Stimulation of the receptor on somatotroph cells drives synthesis and pulsatile release of endogenous growth hormone, with downstream effects on circulating IGF-1.
The compound has an unusually large controlled human evidence base for this class. A phase 3 randomized controlled program in adults with HIV-associated abdominal fat accumulation measured visceral adipose tissue by computed tomography alongside metabolic endpoints (Stanley and colleagues, 2012, Clin Infect Dis), and a long-term extension study examined safety and effect durability in the same population (Falutz and colleagues, 2008, AIDS). The clinical pharmacology of that program is summarized in a published review (Dhillon, 2011, Drugs). These are controlled trials in a specific patient population; the findings characterize the compound as studied there and are not evidence of effect in any other context.
Open questions in the research landscape include the mechanisms underlying the return of visceral adiposity observed after treatment discontinuation in the clinical program, the degree to which the compound's effects are mediated through the GH/IGF-1 axis versus direct receptor actions, and how its pharmacology compares with shorter GHRH fragments such as sermorelin (GHRH 1-29 amide) in matched experimental systems. In laboratory settings, tesamorelin serves as a stabilized GHRH receptor agonist for growth hormone axis research.
This material is supplied as a lyophilized powder with purity verified by HPLC and a published certificate of analysis. It is intended strictly for laboratory research use and is not for human or veterinary use.
Specifications
| Form | Lyophilized powder |
| Purity | >=99% (HPLC) |
| Structure | 44-amino-acid GHRH analog with N-terminal trans-3-hexenoyl group |
| Molecular formula | C221H366N72O67S |
| Molecular weight | 5135.8 g/mol |
| CAS | 218949-48-5 |
| Storage | Store lyophilized at -20C; refrigerate (2-8C) after reconstitution |
Storage & Handling
Store the lyophilized powder at -20C, protected from light and moisture. After reconstitution, refrigerate at 2-8C and use the solution promptly.
For handling guidance, see our peptide reconstitution and storage guide, and use the reconstitution calculator to plan solution volumes for laboratory work.
Certificate of Analysis
🛡 COA — 10mgRelated Compounds
References
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011. PMID 21668043
- Falutz J et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008. PMID 18690162
- Stanley TL et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012. PMID 22495074